Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Melanoma 1Carcinoma, Medullary 1Carcinoid Tumor 1

Interventions

pembrolizumab 17Nivolumab 6Docetaxel 6Gemcitabine 5Cisplatin 5Carboplatin 5durvalumab 4Paclitaxel 4Ipilimumab 4avelumab 3atezolizumab 3Filgrastim 3Cyclophosphamide 3Bortezomib 3130-nm albumin-bound paclitaxel 3tremelimumab 2tislelizumab 2spartalizumab 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2abiraterone 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Nicotine 2Irinotecan 2Interleukin-2 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Dacarbazine × Head & Neck × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡